• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
DCN

DACIAN GOLD LIMITED - Announcements

2.81% ! $2.77
Currently unlisted.
Add to My Watchlist

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements



Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
refresh Created with Sketch. REFRESH
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
Add to My Watchlist

Top Stories

Haranga Resources makes strategic "Mother Lode" acquisition in US

Haranga Resources has entered into a PSA to the key rights to two properties immediately adjacent to its Lincoln gold project in California.
ASX Today: Australian shares fall as retail and banks drag on index Australian shares fall at midday as retail stocks and banks weigh on the ASX 200, while earnings results drive sharp moves across JB Hi-Fi, NAB, Iress and others.
Auking Mining Tundulu rare earth diamond hole intersects carbonatite to EOH AuKing Mining is preparing to further test the depth potential of its Tundulu rare earth project in Malawi after new drilling success.
Tungsten has soared +700% YTD, the US is curbing its exports, and this ASX stock is targeting production in Q1CY27 Right now, the US-Israel-Iranian war in the Middle East and the ongoing war in Ukraine are both increasing global demand for a critical mineral vital for national security and defence: tungsten. While not the whole story of its appeal, tungsten has the highest melting point of any metal and is hi...
Mesoblast completes Phase 3 low back pain trial treatment as pivotal readout approaches Mesoblast has completed treatment of 350 patients in its pivotal Phase 3 trial for chronic low back pain, with results expected in mid-2027.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.